STAT+: Natera, known for spotting cancer recurrence, wades into early detection
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. It seems everyone I know has been getting sick lately — hope you are all taking care of yourselves! Onto the news today.
BridgeBio notches another Phase 3 win
BridgeBio said this morning that its investigational drug succeeded in a late-stage trial of patients with autosomal dominant hypocalcemia type 1, a rare genetic condition that causes low calcium levels in the blood.
Elaine Chen
Go to statnews